蒙药冠心舒通胶囊对急性心肌梗死支架术后再狭窄研究

发布时间：2018-06-08 16:28

本文选题：冠心舒通胶囊 + 急性心肌梗死　；参考：《中国民族医药杂志》2017年03期

【摘要】：目的:探索蒙药冠心舒通胶囊预防急性心肌梗死患者支架植入术后再狭窄的疗效观察。方法:选取2014年5月至2016年1月因急性心肌梗死就诊我院并行急诊支架植入术的患者106例,接受冠心舒通胶囊治疗的患者42例,未接受冠心舒通药物治疗的64例,其中有30例(14例为实验组,16例为对照组)患者1年后进行冠状动脉造影复查,实验组和对照组均用给予冠状动脉粥样硬化性心脏病规范化二级预防药物治疗,依据患者意愿实验组在规范化冠心病二级预防药物治疗基础上加用冠心舒通胶囊,每次3粒,每日3次。术后1年复查冠状动脉造影术,观察两组患者支架内再狭窄发生率有无差别。结果:实验组与对照组两组药物治疗后均无再狭窄的发生。结论:联合应用冠心舒通胶囊可明显减少急性心肌梗死患者PCI术后心绞痛发作。
[Abstract]:Objective: to investigate the efficacy of Guanxin Shutong capsule in preventing restenosis after stent implantation in patients with acute myocardial infarction. Methods: from May 2014 to January 2016, 106 patients with acute myocardial infarction underwent emergency stent implantation, 42 patients were treated with Guanxin Shutong capsule, and 64 patients were not treated with Guanxin Shutong drug. Among them, 30 cases (14 cases) were treated with coronary angiography one year later. The experimental group and control group were treated with standardized secondary prophylaxis of coronary atherosclerotic heart disease. According to the wishes of the patients, the experimental group was treated with Guanxin Shutong capsule on the basis of standardized secondary prophylaxis drug therapy for coronary heart disease, 3 capsules per time, 3 times a day. One year after coronary angiography, the incidence of stent restenosis in the two groups was observed. Results: there was no restenosis in both experimental group and control group. Conclusion: Guanxin Shutong capsule can significantly reduce angina pectoris attack after PCI in patients with acute myocardial infarction.
【作者单位】：内蒙古国际蒙医医院;
【分类号】：R29

【相似文献】